TriangleAcalabrutinib (NCT04941716)
Acalabrutinib trial for Recurrent Chronic Lymphocytic Leukemia (NCT04941716). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with CLL or SLL that returned or resisted treatment and now needs therapy. Prior progression on a BTK inhibitor or venetoclax, and intolerance to acalabrutinib or venetoclax, are excluded.
The idea: combine acalabrutinib’s blockade of growth signals with venetoclax’s blockade of a survival protein. Acalabrutinib starts alone; venetoclax joins in cycle four. Both are oral, with treatment lasting up to 26 28-day cycles. Bone-marrow sampling is required.
This phase 2 study plans 20 patients. Mazyar Shadman leads at Fred Hutch in Seattle, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.